+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

World Human Insulin Market - Opportunities and Forecasts, 2019 - 2026

  • PDF Icon


  • September 2019
  • Region: Global
  • Allied Market Research
  • ID: 3773486

Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood. The global human insulin market is expected to grow at healthy CAGR during the forecast period due to high prevalence of diabetes, worldwide. In-depth analysis of the global human insulin market focuses on various aspects of the market such as market trends, market drivers, restraints and opportunities. Competitive landscape section focuses on key leaders within the global human insulin market and their major growth strategies. Detailed analysis of segments helps in understanding market dynamics and would be beneficial for market professionals.

The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services. Favorable government policies and technological advances such as innovation of insulin pens have also fueled the growth of this market. However, cost of production, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are the factors that could hinder the growth of global human insulin market. Pipeline insulin products and untapped emerging economies are the promising opportunities for the manufacturers of global human insulin.

Global Human Insulin Market by Types
The global human insulin market is segmented by product type into Traditional and Modern Human Insulin. Traditional Human Insulin is segmented as Premixed, Intermediate Acting and Short Acting Human Insulin, whereas Modern Human Insulin includes Premixed, Long Acting and Rapid Acting types. Long acting modern insulin and premixed modern insulin are the fastest growing categories of this segment. 

Global Human Insulin Market by Brands
According to the brands available into the market, the global human insulin market is classified as traditional and modern human insulin brands. Traditional brands include Humulin, Actrapid and Insuman, whereas, modern brands include Humalog, Novomix, Novorapid, Lantus, Levemir and Apidra. Over the past few years, biosimilars has gained popularity in comparison to branded drugs. Basalog, Wosulin and Glaritus are the biosimilars available in Asia-Pacific region. Amongst traditional and modern brands, Lantus holds the largest market share, whereas, Levemir and Apidra are the fastest growing insulin drugs.

Global Human Insulin Market by Geography
Geographically, global human insulin market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America dominates the global human insulin market owing to high prevalence of diabetes and technological advances in effective insulin delivery. Asia-Pacific and LAMEA are the fastest growing geographic segments due to high diabetes incidences, government support and improving healthcare conditions. 
Competitive Landscape
Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and Wockhardt are some of the key players of global human insulin market. Manufacturers are focusing to develop the advanced techniques of insulin delivery to gain the competitive advantage. Development of biosimilars is a booming trend in global human insulin market and Wockhardt and Biocon have launched their biosimilars products in Asia-Pacific region.

High Level Analysis
The study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global human insulin market, their operating strategies, new launches, pipeline products and clinical trials. Porter’s Five Forces analysis has been used to determine the attractiveness of global human insulin market. Large pool of diabetic population and high cost of technology required to manufacture innovative insulin delivery devices are the factors that tend to increase the supplier’s bargaining power. High cost of down streaming process and manunufacturing complexities limit the new players in entering the market. Industrial rivalry is intense due to patent expiration of major brands and growing demand for biosimilars products.


This report offers the following benefits in particular:

  • Comprehensive coverage of global human insulin market along with disease overview, market trends, drivers and restraints
  • Thorough attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
  • Explicit information on current clinical trials and R&D activities would be beneficial to understand the future market trends
  • Insightful analysis of different segments helps to recognize and capitalize future opportunities within global human insulin market

The global human insulin market is segmented into three major categories such as, Product Type, Brand and Geography.


  • Traditional Human Insulin  
    • Premixed Traditional
    • Intermediate Acting
    • Short Acting

  • Modern Human Insulin  
    • Premixed Modern
    • Long Acting
    • Rapid Acting


  • Traditional Human Insulin Brands
    • Humulin 
    • Actrapid
    • Insuman

  • Modern Human Insulin Brands
    • Humalog
    • Novomix
    • Novorapid
    • Lantus
    • Levemir
    • Apidra


  • North America
  • Europe
  • Asia-Pacific

Table of Contents

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models
2.1 CXO Perspective
3.1 Market Definition and Scope
3.2 Key Findings
3.2.1 Top Investment Pockets
3.2.2 Top Winning Strategies
3.3 Top Player Positioning, 2016
3.4 Porter’s Five Forces Analysis
3.5 Market Dynamics
3.5.1 Drivers
3.5.2 Restraints
3.5.3 Opportunities
4.1 Overview
4.1.1 Market size and forecast
4.2 Traditional Human Insulin
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Premixed Traditional Market size and forecast
4.2.5 Intermediate Acting Market size and forecast
4.2.6 Short Acting Market size and forecast
4.3 Modern Human Insulin
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Premixed Modern Market size and forecast
4.3.5 Long Acting Market size and forecast
4.3.6 Rapid Acting Market size and forecast
5.1 Overview
5.1.1 Market size and forecast
5.2 Traditional Human Insulin Brands
5.2.1 Market size and forecast
5.2.2 Humulin Market size and forecast
5.2.3 Actrapid Market size and forecast
5.2.4 Insuman Market size and forecast
5.3 Modern Human Insulin Brands
5.3.1 Market size and forecast
5.3.2 Humalog Market size and forecast
5.3.3 Novomix Market size and forecast
5.3.4 Novorapid Market size and forecast
5.3.5 Lantus Market size and forecast
5.3.6 Levemir Market size and forecast
5.3.7 Apidra Market size and forecast
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S. Market size and forecast
6.2.5 Canada Market size and forecast
6.2.6 Mexico Market size and forecast
6.3 Europe
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.3.4 UK Market size and forecast
6.3.5 France Market size and forecast
6.3.6 Germany Market size and forecast
6.3.7 Italy Market size and forecast
6.3.8 Spain Market size and forecast
6.3.9 Rest of Europe Market size and forecast
6.4 Asia-Pacific
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan Market size and forecast
6.4.5 China Market size and forecast
6.4.6 India Market size and forecast
6.4.7 Australia Market size and forecast
6.4.8 Rest of Asia-Pacific Market size and forecast
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Brazil Market size and forecast
6.5.5 Argentina Market size and forecast
6.5.6 Turkey Market size and forecast
6.5.7 South Africa Market size and forecast
6.5.8 Rest of LAMEA Market size and forecast
7.1 AstraZeneca Plc. (Medimmune, LLC.)
7.1.1 Overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Operating segment overview
7.1.5 Strategic moves and developments
7.2 Glaxosmithkline Plc.
7.2.1 Overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Operating segment overview
7.2.5 Strategic moves and developments
7.3 Merck & Co., Inc.
7.3.1 Overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Operating segment overview
7.3.5 Strategic moves and developments
7.4 Sanofi Pasteur
7.4.1 Overview
7.4.2 Company snapshot
7.4.3 Business performance
7.4.4 Operating segment overview
7.4.5 Strategic moves and developments
7.5 Aduro BioTech Inc.
7.5.1 Overview
7.5.2 Company snapshot
7.5.3 Business performance
7.5.4 Operating segment overview
7.5.5 Strategic moves and developments
7.6 Sanpower Group
7.6.1 Overview
7.6.2 Company snapshot
7.6.3 Business performance
7.6.4 Operating segment overview
7.6.5 Strategic moves and developments
7.7 Astellas Pharma Inc.
7.7.1 Overview
7.7.2 Company snapshot
7.7.3 Business performance
7.7.4 Operating segment overview
7.7.5 Strategic moves and developments
7.8 CSL Limited
7.8.1 Overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Operating segment overview
7.8.5 Strategic moves and developments
7.9 Pfizer Inc.
7.9.1 Overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Operating segment overview
7.9.5 Strategic moves and developments
7.10  Serum Institute of India Pvt. Ltd.
7.10.1 Overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Operating segment overview
7.10.5 Strategic moves and developments

Companies Mentioned

  • Aduro BioTech Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc. (Medimmune, LLC.)
  • CSL Limited
  • Glaxosmithkline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Sanpower Group
  • Serum Institute of India Pvt. Ltd.


The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.